Celica

Celica Biomedical is a Slovenian biotechnology company specializing in the development of personalized cell-based therapies for cancer and other diseases. The company's core technology, the Hybri-D platform, involves the fusion of a patient's dendritic cells with tumor cells to create a potent autologous vaccine that stimulates the immune system to target cancer. Their lead program is a dendritic cell-based vaccine for the treatment of castration-resistant prostate cancer, which has progressed through Phase 1/2 clinical trials. Beyond oncology, Celica is involved in basic research and diagnostic services related to cell biology and neuroendocrinology.